⌘K
Loading ticker…
As of 2026-08-24, Immucell Corp (ICCC) has a 3-month relative strength percentile of 42 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 63. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.4%, relative volume 1.70×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
ICCC is held by 5 ETFs as of Apr 2026. Top owner: DFAT at 0.00% weight, $24K notional. Top 3 carry $45K.
Held by 8 ETFs · $2M across latest filings · largest weight 0.01% (IWC).
Top 5 by value, from SEC N-PORT-P filings dated Apr 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| DFATDimensional U.S. Targeted Value ETF | 0.00% | $24K | — |
| DCOR | 0.00% | $16K | — |
| DFSU | 0.00% | $5K | — |
| DFACDimensional U.S. Core Equity 2 ETF | 0.00% | $914 | — |
| DXUV | 0.00% | $34 | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ICCC Jan avg: 7.17% median: 4.54% win: 75% σ: 10.19% n: 4 2022-04-12 → 2026-07-31 | ICCC Feb avg: -3.52% median: -1.35% win: 25% σ: 12.38% n: 4 2022-04-12 → 2026-07-31 | ICCC Mar avg: -6.30% median: -6.47% win: 25% σ: 5.79% n: 4 2022-04-12 → 2026-07-31 | ICCC Apr avg: 8.06% median: 5.40% win: 60% σ: 16.47% n: 5 2022-04-12 → 2026-07-31 | ICCC May avg: 1.18% median: -3.05% win: 40% σ: 17.55% n: 5 2022-04-12 → 2026-07-31 | ICCC Jun avg: 6.60% median: 7.15% win: 80% σ: 5.83% n: 5 2022-04-12 → 2026-07-31 | ICCC Jul avg: -0.72% median: 1.04% win: 60% σ: 11.65% n: 5 2022-04-12 → 2026-07-31 | ICCC Aug avg: -9.87% median: -11.49% win: 25% σ: 7.93% n: 4 2022-04-12 → 2026-07-31 (current) | ICCC Sep avg: 3.29% median: 0.13% win: 50% σ: 8.72% n: 4 2022-04-12 → 2026-07-31 | ICCC Oct avg: 0.23% median: -0.36% win: 25% σ: 5.16% n: 4 2022-04-12 → 2026-07-31 | ICCC Nov avg: -8.06% median: -11.98% win: 25% σ: 15.67% n: 4 2022-04-12 → 2026-07-31 | ICCC Dec avg: 13.15% median: 18.56% win: 75% σ: 17.77% n: 4 2022-04-12 → 2026-07-31 |